Adherence, Improvement Measure (AIM) System (AIM)
|ClinicalTrials.gov Identifier: NCT01252212|
Recruitment Status : Completed
First Posted : December 2, 2010
Last Update Posted : November 20, 2013
|Condition or disease||Intervention/treatment||Phase|
|Patient Compliance AIDS||Behavioral: SMS medication adherence Behavioral: No SMS adherence reminder||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||99 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Adherence, Improvement Measure (AIM) System; Challenge Topic: 10-MH-101|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||December 2012|
Experimental: Receiving SMS alerts
The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
Behavioral: SMS medication adherence
SMS messages to cell phones.
Other Name: mobile health messages for health conditions and medications
Active Comparator: No SMS messages
The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
Behavioral: No SMS adherence reminder
In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
Other Name: No medication adherence or disease specific messages.
- HIV viral load [ Time Frame: 12 month ]The primary analyses of the 12-month trial data will compare the two study groups with respect to (i) change from baseline in CD4 T-cell count; and (ii) proportion of patients whose HIV viral load (VL) level is detectable. We will use repeated-measures analysis techniques to estimate longitudinal prevalence at the population level (via generalized estimating equations) and at the individual levels (via generalized linear mixed models).
- Level of antiretroviral medication in hair [ Time Frame: 12 month ]We will evaluate the antiretroviral level in hair samples from patients to determine compliance with medications.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01252212
|United States, California|
|Ward 86, San Francisco General Hospital|
|San Francisco, California, United States, 94110|
|Principal Investigator:||James Kahn, MD||University of California, San Francisco|